Is NUVL Worth Buying in 2026?

Nuvalent, Inc. Class A Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-14

Here’s whether Nuvalent, Inc. Class A Common Stock (NUVL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.15% over 10 days); RSI 64 — healthy momentum range; strong 1-year return of +58.2%; 3-month momentum positive (+23.8%); rising volume confirms the move (2.64x 30d avg). Currently 0.3% off its 52-week high. Score: +8/7.

Ready to act on this? 📈 Trade on Webull

NUVL is in a confirmed uptrend, trading above both its 50-day ($104.10) and 200-day ($98.73) moving averages. An RSI of 64.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +58.2% compares to +22.9% for SPY (beat the market by 35.3%).

$10,000 invested 1 year ago → $15,820 today
vs. S&P 500 (SPY) — same period beat market by 35.3%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($98.73)
Above 50-day MA ($104.10)
RSI(14) neutral zone (30–70) — currently 64.5
Positive return (+58.2%)
Within 10% of period high (−0.3%)
Period Range $123.25
$71.13 $123.62
RSI (14) 64.5
0 · OversoldOverbought · 100

Key Metrics

Price$123.25
Period Return+58.2%
Period High$123.62
Period Low$71.13
Drawdown−0.3%
MA-50$104.10
MA-200$98.73
RSI (14)64.5
Avg Volume (30d)3.1M
vs. SPYbeat by 35.3%
Return Rank#313 of 1246

Trade NUVL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers